MetaStat Enters into Agreement to Access Tumor Samples and Clinical Data from Kaiser Foundation Hospitals
27 Janvier 2015 - 2:56PM
Business Wire
Research Represents Next Step Forward in Path
Toward Commercialization of Company’s Diagnostic Tests
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company
focused on developing and commercializing epigenetic-based
diagnostic tests for early and reliable prediction of systemic
metastasis, has executed a material/data transfer agreement with
Kaiser Foundation Hospitals. Under the terms of the agreement,
MetaStat will receive de-identified tissue samples, clinical data
and medical histories for up to 500 patients with or without
metastatic breast cancer for testing using the Company’s MetaSite
Breast™ and MenaCalc Breast™ diagnostic assays for the early and
reliable prediction of systemic metastasis.
“These tissues samples will allow us to independently verify and
validate results from the recently published study1 on the
prediction of distant metastasis of breast cancer by Rohan et al.
in the Journal of the National Cancer Institute,” said Oscar
Bronsther, M.D., MetaStat’s Chief Executive Officer and Chief
Medical Officer. “We look forward to initiating our validation
study using the Kaiser tissue samples later this month and
reporting these data to the medical community later this year.”
About Kaiser Permanente
Kaiser Permanente is recognized as one of America’s leading
health care providers and nonprofit health plans. Founded in 1945,
its mission is to provide high-quality, affordable health care
services to its members and communities. Kaiser Permanente
currently serves approximately 9.5 million members in eight states
and the District of Columbia.
About MetaStat, Inc.
MetaStat, Inc. (MTST) is a molecular diagnostic company that
develops and commercializes diagnostic tests for early and reliable
prediction of systemic metastasis, the process by which cancer
spreads from a primary tumor through the bloodstream to other areas
of the body. MetaStat is focused on breast, prostate, lung and
colorectal cancers, where systemic metastasis is responsible for
approximately 90% of all deaths. The company’s function-based
diagnostic platform technology is based on the identification and
understanding of the pivotal role of the mena protein and its
isoforms, a common pathway for the development of systemic
metastatic disease in all epithelial-based solid tumors. Both the
MetaSite Breast™ and MenaCalc™ assays are designed to accurately
stratify patients based on their individual risk of metastasis and
to provide physicians with clinically actionable information to
better "customize" cancer treatment. MetaStat’s testing platform
improves treatment planning decisions by positively identifying
patients with a high-risk of metastasis who need aggressive therapy
and by sparing patients with a low-risk of metastasis from the
harmful side effects and expense of chemotherapy. The company is
based in Boston.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and such forward-looking statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause
future circumstances, events or results to differ materially from
those projected in the forward-looking statements as a result of
various factors and other risks, including those set forth in the
company's Form 10-K filed with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and the company undertakes
no obligation to update such statements.
1. Rohan TE, XueX, Lin HM, et al. Tumor microenvironment of
metastasis and risk of distant metastasis of breast cancer. J Natl
Cancer Inst. 2014 June 3;106(8). pii: dju136. doi:
10.1093/jnci/dju136. Print 2014 Aug.
Media:Dian Griesel Int’l. for MetaStatSusan Forman,
212-825-3210sforman@dgicomm.comorInvestors:MetaStat,
Inc.Douglas Hamilton, (917) 597-4164Dhamilton@metastat.com
MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
